China Biopharmaceuticals (01177.HK): LM-2417 "NaPi2b/4-1BB bispecific antibody" completes the enrollment of the first patient in Phase I clinical trial in China.

Zh tng cijng APP xn, Zhnggu shngw zhyo (01177.HK) fb gnggo, gngs qunz fsh gngs l xn yyo kj (shnghi) yuxin gngs (l xn yyo) zzh ynf de guji 1 li chungxn yo LM-2417 "NaPi2b/4-1BB shung tyng xng kngt" zi zhnggu kizhn de I q lngrn shyn y shnl wnchng shu l hinz, biozhzhe zh y chungxn liof zhngsh jnr lngrn kif jidun.